Company Overview

Tata Chemicals Limited reported its Integrated Annual Report for FY2025-26, covering consolidated financial performance, strategic initiatives, and regulatory compliance. The company operates in basic chemistry and specialty products with global presence through subsidiaries in USA, UK, Kenya, and Singapore.

Financial Performance Highlights

Consolidated Performance (₹ crore)

  • Revenue from Operations: 14,584 (FY25: 14,887) - decline of 2%
  • EBITDA: 1,805 (FY25: 1,953) - decline of 8%
  • Profit Before Tax: (1,459) (FY25: 521)
  • Profit After Tax: (1,715) (FY25: 354)
  • Exceptional Items: (1,956) crore including ₹1,837 crore goodwill impairment related to US operations
  • Total Comprehensive Income: 75 crore (FY25: (114))

Standalone Performance (₹ crore)

  • Revenue from Operations: 4,831 (FY25: 4,441) - growth of 9%
  • EBITDA: 954 (FY25: 818) - growth of 17%
  • Profit Before Tax: 672 (FY25: 624)
  • Profit After Tax: 606 (FY25: 524)

Capital Structure & Financing

  • Share Capital: ₹255 crore (unchanged)
  • Networth: ₹22,175 crore (Consolidated), ₹19,308 crore (Standalone)
  • Borrowings: ₹8,001 crore (Consolidated), ₹3,487 crore (Standalone)
  • Net Debt to Equity: 0.31 times (Consolidated), 0.17 times (Standalone)
  • Issued ₹1,500 crore listed NCDs at 7.06% on December 17, 2025

Segment Performance Analysis

Basic Chemistry Products

  • Soda Ash sales: 8.27 lakh MT (15.3% growth) but facing global oversupply pressures
  • Sodium Bicarbonate sales: 1.96 lakh MT (33% growth)
  • Salt sales: 14.42 lakh MT (6.6% growth)

Subsidiaries Performance

  • TCNA (USA): Revenue ₹4,936 crore (6% decline), EBITDA ₹294 crore (55% decline) - impacted by impairment
  • UK Operations: Revenue ₹1,461 crore (27% decline), EBITDA ₹88 crore
  • TCML (Kenya): Revenue ₹586 crore (4% decline), EBITDA ₹101 crore (29% decline)
  • Rallis India: Revenue ₹2,897 crore (9% growth), EBITDA ₹364 crore (26% growth)

Strategic Initiatives & Expansion

Novabay Acquisition

  • Acquired 100% equity of Novabay Pte. Limited, Singapore
  • Adds 60 KTPA premium-grade sodium bicarbonate capacity
  • Strengthens pharmaceutical and healthcare market presence with cGMP and API approvals

Capacity Expansion

  • Commissioned 3.5 KTPA Microsphere Silica capacity
  • Commissioned 4.5 KTPA L55 fermentation line for prebiotics
  • 50 KTPA vacuum salt capacity added
  • 210 KTPA IVSD Salt plant in Tamil Nadu underway

Digital Transformation

  • Launched Unified Digital Core on SAP and Ariba
  • Implemented 100+ process improvements
  • Established Data Office and Microsoft Fabric Lakehouse
  • Deployed AI, IoT and automation across manufacturing

Sustainability Performance

  • Scope 1 Emissions: 48,50,029 tCO₂e
  • Scope 2 Emissions: 1,09,860 tCO₂e
  • Water Consumption: 2,34,46,643 KL
  • 5 MW solar plant commissioned at Magadi, Kenya
  • Target: Carbon Net Zero by 2045

Regulatory Compliance & Governance

Secretarial Audit Findings

  • Parikh & Associates confirmed compliance with Companies Act, SEBI Regulations, and other applicable laws
  • Board duly constituted with 7 members including 4 Independent Directors
  • 8 Board meetings conducted during FY25-26

Contingent Liabilities

  • Tax matters: ₹833 crore in disputes with income tax authorities
  • Land rates demand in Kenya: ₹891 crore (under legal dispute)
  • Other claims and litigation: ₹116 crore

Related Party Transactions

  • Total transactions: ₹177 crore with Tata group entities
  • All transactions at arm's length and in ordinary course of business

Dividend & Corporate Actions

  • Recommended final dividend of ₹11.00 per share (110%)
  • Record Date: June 10, 2026
  • Payment Date: On or after June 30, 2026
  • 87th AGM scheduled for June 26, 2026 via video conference

Risk Management & Outlook

Key risks identified include sustainability challenges, global soda ash overcapacity, digital transformation needs, and talent acquisition. Mitigation strategies focus on cost optimization, supply chain resilience, and sustainability initiatives. The company maintains a cautious FY2027 outlook amid continued global market challenges, particularly in the basic chemistry segment.